HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

ciprofibrate

Subscribe to New Research on ciprofibrate

Also Known As:

Hyperlipen; Lipanor; Modalim; Oroxadin; Sanofi Synthelabo brand of ciprofibrate; Sanofi Winthrop brand of ciprofibrate; Win 35,833; 2-(4-(2,2-dichlorocyclopropyl)phenoxy)2-methylpropanoic acid

Networked: 126 relevant articles (4 outcomes, 24 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 58

Experts

1.	Fu, Tao: 3 articles (07/2004 - 08/2003)
2.	Borensztajn, Jayme: 3 articles (07/2004 - 08/2003)
3.	Karge, Elke: 2 articles (01/2008 - 07/2005)
4.	Lupp, Amelie: 2 articles (01/2008 - 07/2005)
5.	Deufel, Thomas: 2 articles (01/2008 - 07/2005)
6.	Spear, Brett T: 2 articles (04/2006 - 10/2003)
7.	Tharappel, Job C: 2 articles (04/2006 - 10/2003)
8.	Glauert, Howard P: 2 articles (04/2006 - 10/2003)
9.	Rao, M Sambasiva: 2 articles (05/2003 - 03/2002)
10.	Waldum, Helge L: 2 articles (03/2003 - 09/2002)

Related Diseases

1.	Hyperlipidemias (Hyperlipidemia) 11/01/1990 - "Efficacy of ciprofibrate in primary type II and IV hyperlipidemia: the Italian multicenter study." 07/01/2005 - "The effect of ciprofibrate on flow-mediated dilation and inflammatory markers in patients with combined hyperlipidemia." 01/01/1998 - "Effect of ciprofibrate on platelet aggregation in patients with combined hyperlipidemia." 04/01/1993 - "In conclusion, our findings indicate that ciprofibrate treatment in combined hyperlipidemia results in marked reduction in plasma triglyceride levels (-33%), and that such reduction is intimately linked to normalisation of both the qualitative and quantitative features of the atherogenic LDL subspecies profile typical of this disorder." 04/18/2000 - "Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus."
2.	Dyslipidemias (Dyslipidemia) 07/23/2004 - "Our objective was to evaluate the efficacy of ciprofibrate for the treatment of this form of dyslipidemia and to identify factors associated with better treatment response. " 03/01/2007 - "Thus, the aim of this study was to determine the effects of ciprofibrate on lipid profile in patients with Frederickson's type IV dyslipidemia phenotype. " 03/01/2007 - "Seventy-five patients with type IV dyslipidemia were assigned at random to 1 of 2 therapeutic options: group A (control), American Heart Association (AHA) Step II diet and physical activity; and group B, AHA diet, physical activity, and ciprofibrate 100 mg daily for 8 weeks. " 05/01/2002 - "The effect of treatment with ciprofibrate (100 mg once daily) was investigated for 8 weeks in 30 patients with primary dyslipidemia. " 04/15/2001 - "[Effect of ciprofibrate on the endothelial dysfunction of patients with combined dyslipidemia]."
3.	Hypercholesterolemia 08/01/1982 - "We conclude that once daily therapy with 100 mg ciprofibrate, is effective in reducing LDL levels in patients with type II hypercholesterolemia (mainly heterozygous FH) and that this decrease is paralleled by small rises in HDL." 08/01/1982 - "The hypolipidemic efficacy of ciprofibrate was evaluated in patients with type II hypercholesterolemia. " 08/01/1982 - "Ciprofibrate in the therapy of type II hypercholesterolemia. " 12/26/2003 - "Treatment of apoE-deficient mice with ciprofibrate or other peroxisome proliferator-activated receptor alpha agonists severely aggravates their hypercholesterolemia by interfering with one or more mechanisms of remnant removal from the circulation that do not require mediation by apoE (Fu, T., Kashireddy, P., and Borensztajn, J. " 12/01/1979 - "Ciprofibrate, a new orally effective hypolipidemic agent like clofibrate, suppressed tyloxapol-induced hypercholesterolemia in rats. "
4.	Coronary Artery Disease (Coronary Atherosclerosis) 02/01/1979 - "The order of hypolipidemic effectiveness of ciprofibrate in hyperlipidemic rats provides a basis for anticipating that ciprofibrate will be hypolipidemic in hyperlipoproteinemic subjects who are considered at high risk of acquiring coronary artery disease." 03/01/2006 - "[Changes in serum lipids, plasma fibrinogen and other haemostatic parameters induced by ciprofibrate action in hyperlipidemic patients with and without coronary artery disease]." 11/01/1996 - "The effect of the simvastatin-ciprofibrate combination in comparison with each drug alone on the lipoprotein abnormality patterns was studied in patients with FCHL and coronary artery disease (CAD). " 11/01/2004 - "Soluble vascular cell adhesion molecule-1 (sVCAM-1), soluble intercellular adhesion molecule-1 (sICAM-1) and soluble E-selectin plasma concentrations were measured in 10 obese dyslipidemic men (group A), in 10 obese dyslipidemic type 2 diabetic men without coronary artery disease (CAD) (group B), and in 10 dyslipidemic type 2 diabetic men with angiographically documented CAD (group C) before and after 12 weeks of treatment with ciprofibrate. " 11/01/1996 - "Effects of simvastatin and ciprofibrate alone and in combination on lipid profile, plasma fibrinogen and low density lipoprotein particle structure and distribution in patients with familial combined hyperlipidaemia and coronary artery disease."
5.	Familial Combined Hyperlipidemia (Combined Hyperlipidemia, Familial) 09/01/1997 - "The present study investigated the safety and efficacy of combined pravastotin or simvastatin with gemfibrozil or ciprofibrate treatment on total cholesterol, LDL, TG, plasma fibrinogen, and apoproteins B and A-I in patients with refractory familial combined hyperlipidemia, with or without coronary artery disease. "

Related Drugs and Biologics

1.	Gemfibrozil (Lopid)
2.	Simvastatin (Zocor)
3.	Fibrinogen (Factor I)
4.	Apolipoproteins B (ApoB)
5.	LDL Cholesterol
6.	ciprofibrate
7.	Bezafibrate
8.	Fenofibrate (CiL)
9.	DNA (Deoxyribonucleic Acid)
10.	Clofibric Acid

Related Therapies and Procedures

1.	Oral Administration
2.	Intraperitoneal Injections
3.	Highly Active Antiretroviral Therapy (HAART)
4.	Injections